DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Zepbound (tirzepatide 5–15mg) costs $549/month via LillyDirect direct cash-pay, $25/month with insurance + savings card, or up to $1,349/month retail. Updated for 2026.
Same drug, different pricing channels. The spread is often $800-1000/month between cheapest and retail cash.
Zepbound retail cash-pay is $1,349 per month. LillyDirect direct cash-pay reduces this to $549/month for the maintenance dose (5mg+) or $399/month for the 2.5mg starter dose. LillyDirect ships from Lilly's direct pharmacy — same FDA-approved Zepbound, no middleman markup.
If your commercial insurance covers Zepbound after PA, the Lilly savings card brings the copay as low as $25/month for up to 12 months. Standard out-of-pocket without the savings card runs $50–$150/month depending on tier. The OSA-with-obesity FDA indication (December 2024) makes Zepbound easier to approve than Wegovy on many plans.
Three programs reduce Zepbound cost: (1) Lilly savings card — $25/month if commercially insured, valid 12 months; (2) LillyDirect direct cash-pay — $549/month maintenance or $399/month starter, no insurance required; (3) Patient assistance for income-eligible uninsured.
Medicare Part D historically excluded weight-loss tirzepatide. The OSA-with-obesity FDA indication (December 2024) opened a coverage pathway for Medicare Advantage members with documented sleep apnea (AHI ≥15) plus obesity.
Medicaid coverage varies by state. As of 2026, fewer than 12 states cover Zepbound for weight loss. The OSA indication unlocks coverage on additional plans — submit sleep study + obesity ICD-10 together for fastest approval.
$249–$349/month — same active ingredient (tirzepatide), not FDA-approved as Zepbound. 503A pharmacy compounding. FDA enforcement risk after shortage end.
$499/month via NovoCare direct — different molecule, more cardiovascular outcomes data via SELECT trial. Lower weight loss in head-to-head trial.
Same molecule as Zepbound but FDA-approved for type 2 diabetes only. Off-label weight-loss prescribing increasingly denied in 2026.
Zepbound out-of-pocket cost ranges from $25/month (covered + savings card) to $1,349/month (retail). The realistic cash-pay floor is $399/month for starter dose via LillyDirect, or $549/month for maintenance. If you have sleep apnea, the OSA pathway dramatically improves coverage odds.
Pricing verified monthly against current manufacturer and pharmacy formularies. Coverage rules vary by plan — verify against your member portal before prescribing.